In today’s briefing:
- Catalent Inc.: Leveraging Gene Therapy Expertise But Is It Enough? – Major Drivers
- Veeva Systems: Continued Expansion and Adoption of Vault Platform As A Key Growth Lever! – Major Drivers
Catalent Inc.: Leveraging Gene Therapy Expertise But Is It Enough? – Major Drivers
- Catalent, in its first quarter of fiscal year 2024, has displayed a robust start influenced by solid financial performance, despite the ongoing macroeconomic challenges.
- The company reported a year-over-year revenue stabilization excluding the impact of COVID-19, with a noted 5% revenue increase in non-COVID sectors.
- This performance is underpinned by notable demands in gene therapy services and strategic expansions in the GLP1 (glucagon-like peptide-1) domain, which collectively portend a continuation of mid to high-teens revenue growth for the fiscal year.
Veeva Systems: Continued Expansion and Adoption of Vault Platform As A Key Growth Lever! – Major Drivers
- Veeva Systems reported its fiscal second quarter results for 2025, showcasing strong performance with totals exceeding guidance.
- For the quarter ending July 31, 2024, the company achieved total revenue of $676 million and a non-GAAP operating income of $280 million.
- These figures reflect Veeva System’s robust product strategy execution, including strategic customer wins and key product expansions, such as the release of Veeva Site Connect and the introduction of Service Center in the CRM suite.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
